New Frontier: Developing Outcome Measures for Pre-dementia Trials

• 3 Comments

09 Apr 2013

lengths for clinical trials of potential disease-modifying therapies in MCI would be one year, 18 months,

Focus on the Locus! (Ceruleus, That Is, in Alzheimer’s Disease)

• 3 Comments

22 Dec 2010

This Webinar recapped the latest research in this area. Michael Heneka of the University of Bonn, Germany, and Doug Feinstein of the University of Illinois, Chicago, gave presentations, and were joined in a panel discussion by Virgil Muresan, New Jersey M

Cerebrometabolic Deficiency in Alzheimer's Disease

• 2 Comments

22 Apr 2002

J Neural Transm 1998;(105):415-422. Abstract. 18. Sorbi S, Bird ED, Blass JP. Decreased pyruvate

Differential Neuronal Vulnerability

• 2 Comments

29 Jun 2005

dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis, 18, 19-31.

Targeting Tumor Necrosis Factor—A Therapeutic Strategy for AD

• 2 Comments

29 May 2008

affected the clinical status of patients with moderate to severe heart failure (18-20). Etanercept (Enbrel)

Meet New Players, Histone Deacetylase and Sirtuin—Will They Help the Cell Cycle, DNA Repair, and Gene Expression Break Into Alzheimerology’s Major League?

• 2 Comments

10 Feb 2009

but alters gene expression during aging. Cell. 2008 Nov 28;135(5):907-18. Abstract 0 Thursday,

The Neuroplasticity Theory of Alzheimer's Disease

• 1 Comment

08 Apr 2002

J. Wesson Ashford led this live discussion on 8 April 2002. Readers are invited to submit additional comments by using our Comments form at the bottom of the page. Transcript: Live discussion held Tuesday, 8 April 2002 Participants: John Wesson Ashford (W

Vascular Disease, Parkinson's, and Now Alzheimer's—Is Homocysteine the New All-Around Bad Guy?

• 1 Comment

12 May 2002

deficiency in AβPP-mutant mice in old age of your mice (about 18 months), but before amyloid deposition? Just

How the Other Half Lives—Or the What, How, and Where of the AβPP Intracellular Domain

• 1 Comment

20 Sep 2002

Leissring: Kalpana White has done the most work in this area. Torroja et al., J Neurosci 19(18):7793 is one.

How Does Excess Aβ Leave the Brain, How Does It Get In, And Can We Trap It Outside?

• 1 Comment

23 Jun 2003

1998;70:210-215. Abstract 18. Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B, Zlokovic BV.

Is Alzheimer's an Autoimmune Disease?

• 1 Comment

04 Dec 2003

of autoantibodies occur in control and AD serum. This may be changing now. A recent study of 18 AD

Are Glia Active Participants in Neurodegenerative Disease?

• 1 Comment

05 Dec 2005

Ben Barres led the first in a series of Alzforum discussions about the role of glial cells in Alzheimer’s and other neurodegenerative diseases. It has become trendy to say that glia are more than just glue, but in reality, science has not yet advanced sig

Probing PPARγ? Agonists: Could Diabetes Drugs Treat Alzheimer's Disease?

• 1 Comment

16 Dec 2002

with 30 patients. The study uses pioglitazone at 45 mg/day for 18 months. The primary outcome measures

The Pathogen Hypothesis

• 1 Comment

24 Nov 2008

J Pathol. 2008 Sep 18. Abstract   References [1] Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ,

Are Neurons Just Too Laissez-Faire about Repair?

• 1 Comment

24 Jul 2003

Thierry Nouspikel led this live discussion on 14 July 2003. Readers are invited to submit additional comments by using our Comments form at the bottom of the page. Transcript: Dr. Thierry Nouspikel led this live discussion on 14 July 2003. Moderated by Dr